---
layout: default
title: Panitumumab
parent: 僅模型預測 (L5)
nav_order: 752
evidence_level: L5
indication_count: 10
---

# Panitumumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Panitumumab: From Anti-EGFR Antibody Therapy to Drug-Induced Osteoporosis

## One-Sentence Summary

Panitumumab is a fully human anti-EGFR monoclonal antibody; the evidence pack does not record its originally approved indication or detailed mechanism of action (both flagged as data gaps). The TxGNN model's top prediction is **Drug-Induced Osteoporosis**, but this and all 9 other ranked candidates are currently supported by **zero clinical trials** and **zero publications** — the prediction rests entirely on knowledge-graph embedding similarity.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack (no licensed indication text on file) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for panitumumab is not available in this evidence pack (flagged as a High-severity data gap). Based on the information that is available, panitumumab is a fully human anti-EGFR monoclonal antibody. The pack's own rationale notes that EGFR signaling has a partial, indirect role in osteoblast/osteoclast differentiation — but there is no direct evidence that anti-EGFR therapy can reverse or treat drug-induced osteoporosis.

All 10 ranked predictions (drug-induced osteoporosis, diabetic retinopathy variants, and several cataract subtypes) share the same pattern: a plausible-sounding but weak biological rationale linking EGFR signaling to the target tissue, with **no clinical trials, no ICTRP registrations, and no PubMed literature** returned for any drug-disease pair (see query log, 30 zero-result searches across ClinicalTrials.gov, ICTRP, and PubMed). Several rationales explicitly flag the connection as speculative or possibly KG noise (e.g., tetanic cataract, craniostenosis cataract).

Because the original indication and MOA are both data gaps, and no external evidence corroborates any of the 10 candidates, this prediction should be treated as a hypothesis-generation signal only, not a validated repurposing lead.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Panitumumab is not currently registered in the Singapore market (0 licenses on file; market status: Not Marketed).

---

## Cytotoxicity

Panitumumab's own evidence-pack rationale text identifies it as a targeted anti-EGFR monoclonal antibody (referred to internally as a "腫瘤標靶藥物" / tumor-targeted agent), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All 10 TxGNN-predicted indications are L5 (model prediction only) with zero corroborating clinical trials or literature, and a Blocking-severity data gap exists for TFDA/local regulatory safety information — insufficient basis to advance any candidate past initial screening.

**To proceed, the following is needed:**
- TFDA (or local regulator) package insert — warnings, contraindications (DG001, Blocking)
- Confirmed mechanism of action from DrugBank or primary literature (DG002, High)
- Original approved indication(s) for panitumumab, to properly assess mechanistic similarity to the predicted indications
- Preclinical or case-level evidence specifically linking anti-EGFR therapy to drug-induced osteoporosis before further evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

